{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:43:32Z","timestamp":1768484612192,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.critrevonc.2021.103242","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T03:03:25Z","timestamp":1612321405000},"page":"103242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review"],"prefix":"10.1016","volume":"159","author":[{"given":"Gianluca","family":"Ingrosso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Becherini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1784-7203","authenticated-orcid":false,"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-5864","authenticated-orcid":false,"given":"Emanuele","family":"Al\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2262-1102","authenticated-orcid":false,"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ausilia","family":"Teriaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6251-8903","authenticated-orcid":false,"given":"Alessandro","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-7869","authenticated-orcid":false,"given":"Andrea Riccardo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-1406","authenticated-orcid":false,"given":"Giuseppe","family":"Sanguineti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-5924","authenticated-orcid":false,"given":"Beatrice","family":"Detti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103242_bib0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0015","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0020","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"De Meerleer","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-017-0893-x","article-title":"Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial","volume":"12","author":"De Wolf","year":"2017","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0030","doi-asserted-by":"crossref","first-page":"e000535","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0035","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.juro.2008.05.006","article-title":"Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma","volume":"180","author":"Eggener","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0040","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1084\/jem.180.2.525","article-title":"Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis","volume":"180","author":"Haimovitz-Friedman","year":"1994","journal-title":"J. Exp. Med."},{"issue":"Suppl 6","key":"10.1016\/j.critrevonc.2021.103242_bib0050","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC)","volume":"38","author":"Hammers","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0000000000000622","article-title":"Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"43","author":"He","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0060","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2019.00490","article-title":"Targeting the tumor microenvironment in renal cell Cancer biology and therapy","volume":"9","author":"Heidegger","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0065","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0070","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0075","article-title":"Immunotherapy for renal cell carcinoma","volume":"2010","author":"Itsumi","year":"2010","journal-title":"Clin. Dev. Immunol."},{"issue":"Suppl 6","key":"10.1016\/j.critrevonc.2021.103242_bib0080","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.2020.38.6_suppl.613","article-title":"Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): first results of phase II NIVES study","volume":"38","author":"Masini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0085","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3171\/2016.4.SPINE16229","article-title":"Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma","volume":"25","author":"Miller","year":"2016","journal-title":"J. Neurosurg. Spine"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0090","series-title":"Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique","author":"Moga","year":"2012"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0095","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0100","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003649","article-title":"Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses","volume":"4","author":"Seung","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00345-010-0560-4","article-title":"Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis","volume":"28","author":"Staehler","year":"2010","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic tdenginarapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.radonc.2018.04.028","article-title":"Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014","volume":"127","author":"Stenman","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0135","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103242_bib0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.aaf2784","article-title":"Metastasis as an evolutionary process","volume":"352","author":"Turajlic","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2021.103242_bib0145","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:37:52Z","timestamp":1760902672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"alternative-id":["S1040842821000305"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103242","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103242"}}